MoonLake Immunotherapeutics于2026年美国皮肤病学会(AAD)年会上,正式公布了其创新药物Sonelokimab用于治疗中重度化脓性汗腺炎的三期临床试验第40周关键数据。此次公布的结果进一步验证了该药物持久的疗效与良好的安全性特征,为患者提供了新的治疗希望。
MoonLake Immunotherapeutics于2026年美国皮肤病学会(AAD)年会上,正式公布了其创新药物Sonelokimab用于治疗中重度化脓性汗腺炎的三期临床试验第40周关键数据。此次公布的结果进一步验证了该药物持久的疗效与良好的安全性特征,为患者提供了新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.